Shilpa Biologics permitted to conduct Phase 1 study on NavAlbumin
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The product is synthetically developed as compared to the current process of drawing the same from blood plasma and is backed by a granted global patent
The injunction order has been passed against Natco Pharma, Torrent Pharmaceuticals, Eris Lifesciences and Windlas Biotech
Its unique technology, ChetoSensar gives new promise to ADCs by alleviating solubility challenges
Key takeaways of recent quarter & conference call highlights
The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations
The panel concurred that these supplements resolved post-Covid-19 fatigue and muscle weakness
U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma
Everlife leads the series A round, and SPRIM Global Investments participates in the financing syndicate
Emkay Research expects Q2FY22 to be a normalised quarter for pharma companies that it tracks. A summary of the report
Transformational partnership establishes PCI as a CDMO and broadens capabilities across drug product lifecycle
Subscribe To Our Newsletter & Stay Updated